The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Lieu, Christopher H ^a   Tran, Hai ^b   Jiang, Zhi Qin ^b   Mao, Muling ^b   Overman, Michael J ^b   Lin, E ^b   Eng, Cathy ^b   Morris, Jeffrey ^b   Ellis, Lee ^b   Heymach, John V ^b   Kopetz, Scott ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; IRINOTECAN; OXALIPLATIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D;

ADULT; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIGANDS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84885458908     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077117     Document Type: Article

References (36)

1. Folkman J, (1990) What Is the Evidence That Tumors Are Angiogenesis Dependent? J Natl Cancer Inst 82: 4-7. doi:10.1093/jnci/82.1.4. PubMed: 1688381.
2. Hanahan D, Folkman J, (1996) Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis. Cell 86: 353-364. doi:10.1016/S0092-8674(00)80108-7. PubMed: 8756718.
3. Hicklin DJ, Ellis LM, (2005) Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis. J Clin Oncol 23: 1011-1027. PubMed: 15585754.
4. Hanahan D, Weinberg RA, (2000) The Hallmarks of Cancer. Cell 100: 57-70. doi:10.1016/S0092-8674(00)81683-9. PubMed: 10647931.
5. Bergers G, Hanahan D, (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603. doi:10.1038/nrc2442. PubMed: 18650835.
6. Ferrara N, Gerber H-P, LeCouter J, (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676. doi:10.1038/nm0603-669. PubMed: 12778165.
7. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PAE, et al. (2003) The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 200: 183-194. doi:10.1002/path.1339. PubMed: 12754739.
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med 350: 2335-2342. doi:10.1056/NEJMoa032691. PubMed: 15175435.
9. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, et al. (2008) Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. J Clin Oncol 26: 2013-2019. doi:10.1200/JCO.2007.14.9930. PubMed: 18421054.
10. Ellis LM, Hicklin DJ, (2008) Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy. Clin Cancer Res 14: 6371-6375. doi:10.1158/1078-0432.CCR-07-5287. PubMed: 18927275.
11. Casanovas O, Hicklin DJ, Bergers G, Hanahan D, (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309. doi:10.1016/j.ccr.2005.09.005. PubMed: 16226705.
12. Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda Dan G, et al. (2007) AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients. Cancer Cell 11: 83-95. doi:10.1016/j.ccr.2006.11.021. PubMed: 17222792.
13. Kerbel RS, (2005) Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell 8: 269-271. doi:10.1016/j.ccr.2005.09.016. PubMed: 16226701.
14. Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y, et al. (2004) Comparative Evaluation of FGF-2-, VEGF-A-, and VEGF-C-Induced Angiogenesis, Lymphangiogenesis, Vascular Fenestrations, and Permeability. Circ Res 94: 664-670. doi:10.1161/01.RES.0000118600.91698.BB. PubMed: 14739162.
15. Hindryckx P, Waeytens A, Laukens D, Peeters H, Van Huysse J, et al. (2010) Absence of placental growth factor blocks dextran sodium sulfate-induced colonic mucosal angiogenesis, increases mucosal hypoxia and aggravates acute colonic injury. Lab Invest 90: 566-576. doi:10.1038/labinvest.2010.37. PubMed: 20142801.
16. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, et al. (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583. doi:10.1038/87904. PubMed: 11329059.
17. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, et al. (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9: 936-943. doi:10.1038/nm884. PubMed: 12796773.
18. Eriksson A, Cao R, Pawliuk R, Berg S-M, Tsang M, et al. (2002) Placenta Growth Factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 1: 99-108. doi:10.1016/S1535-6108(02)00028-4. PubMed: 12086892.
19. Björndahl M, Cao R, Eriksson A, Cao Y, (2004) Blockage of VEGF-Induced Angiogenesis by Preventing VEGF Secretion. Circ Res 94: 1443-1450. doi:10.1161/01.RES.0000129194.61747.bf. PubMed: 15192038.
20. Valtola R, Salven P, Heikkilä P, Taipale J, Joensuu H, et al. (1999) VEGFR-3 and Its Ligand VEGF-C Are Associated with Angiogenesis in Breast Cancer. Am J Pathol 154: 1381-1390. doi:10.1016/S0002-9440(10)65392-8. PubMed: 10329591.
21. Pepper MS, Mandriota SJ, Jeltsch M, Kumar V, Alitalo K, (1998) Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J Cell Physiol 177: 439-452. doi:10.1002/(SICI)1097-4652(199812)177:3. PubMed: 9808152.
22. Saaristo A, Veikkola T, Enholm B, HYTÖNEN M, Arola J, et al. (2002) Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J 16: 1041-1049. doi:10.1096/fj.01-1042com. PubMed: 12087065.
23. Weickhardt A, Williams D, Lee C, Simes J, Murone C, et al. (2011) Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study. J Clin Oncol 29.
24. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, et al. (2009) Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. J Clin Oncol JCO.(2009): pp. 2024.8252. PubMed: 20008624.
25. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, et al. (2009) Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study. J Clin Oncol 27: 3020-3026. doi:10.1200/JCO.2008.21.1771. PubMed: 19470921.
26. Hansen B, Klopfer S, (2006) Optimal full matching and related designs via network flows. JCGS 15: 609-627.
27. Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, et al. (2009) Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol 28: 193-201. PubMed: 19949019.
28. Adler D, (2005) Vioplot: violin plot.
29. Broll R, Erdmann H, Duchrow M, Oevermann E, Schwandner O, et al. (2001) Vascular endothelial growth factor (VEGF) - a valuable serum tumour marker in patients with colorectal cancer? Eur J Surg Oncol (EJSO) 27: 37-42. doi:10.1053/ejso.2000.1052.
30. Matsumoto K, Suzuki K, Koike H, Okamura K, Tsuchiya K, et al. (2003) Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res 23: 4953-4958. PubMed: 14981951.
31. Parr C, Watkins G, Boulton M, Cai J, Jiang WG, (2005) Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer 41: 2819-2827. doi:10.1016/j.ejca.2005.07.022. PubMed: 16275058.
32. Ribatti D, (2008) The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis 11: 215-221. doi:10.1007/s10456-008-9114-4. PubMed: 18568405.
33. Yao J, Wu X, Zhuang G, Kasman IM, Vogt T, et al. (2011) Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proceedings of the National Academy of Sciences.
34. Grothey A, Sobrero A, Siena S, Falcone A, Ychou M, et al. (2012) Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. J Clin Oncol 30.
35. Bagley RG, Ren Y, Weber W, Yao M, Kurtzberg L, et al. (2011) Placental Growth Factor Upregulation Is a Host Response to Antiangiogenic Therapy. Clin Cancer Res 17: 976-988. doi:10.1158/1078-0432.CCR-10-2687. PubMed: 21343374.
36. Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, et al. (2012) VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 13: 724-733. doi:10.1016/S1470-2045(12)70231-0. PubMed: 22608783.